Spelling suggestions: "subject:"platelet"" "subject:"latelet""
11 |
An investigation into platelet heterogeneityRobinson, Monique Samantha Chantal January 2001 (has links)
No description available.
|
12 |
Fibrinolytic and endothelial markers in cardiovascular disease and diabetes mellitusRumley, Ann January 1996 (has links)
No description available.
|
13 |
Receptor-mediated stimulation of human platelet phosphoinositide metabolismPollock, K. January 1984 (has links)
No description available.
|
14 |
Regulation of platelet function by cytosolic free calcium and cyclic AMPBushfield, M. January 1986 (has links)
No description available.
|
15 |
Desensitisation and potentiation of platelet inositol phospholipid hydrolysisMcNicol, A. January 1986 (has links)
No description available.
|
16 |
The relationship between platelet-vessel wall interaction thrombosis and atherosclerosisLane, I. F. January 1987 (has links)
No description available.
|
17 |
The mechanisms of platelet activating factor induced alterations in lung functions /Göggel, Rolf. January 2002 (has links)
Lübeck, University, Thesis (doctoral), 2001.
|
18 |
Platelet GPIb and downstream activation by S. sanguisAbdulrehman, Ahmed Y. 13 December 2010 (has links)
There is increasing evidence suggesting the contribution of bacterial infections in atherothrombotic conditions. Studies have demonstrated that bacteria residing within the oral cavity activate platelets once they enter circulation. S. sanguis 2017-78 is capable of stimulating platelet aggregation in a thromboxane-dependent manner. In the present study, the signaling events associated with S. sanguis have been studied further. S. sanguis 2017-78 caused the phosphorylation of p38 MAP kinase and subsequently cPLA2. The p38 MAP kinase inhibitor, SB203580 inhibited S. sanguis 2017-78-induced platelet aggregation as well as the phosphorylation of both p38 MAP kinase and cPLA2. These data are consistent with cPLA2 as a physiological target of p38.
A second component of the study examined the effects of aspirin, a known inhibitor of cyclooxygenase, on these signalling pathways.
|
19 |
Platelet GPIb and downstream activation by S. sanguisAbdulrehman, Ahmed Y. 13 December 2010 (has links)
There is increasing evidence suggesting the contribution of bacterial infections in atherothrombotic conditions. Studies have demonstrated that bacteria residing within the oral cavity activate platelets once they enter circulation. S. sanguis 2017-78 is capable of stimulating platelet aggregation in a thromboxane-dependent manner. In the present study, the signaling events associated with S. sanguis have been studied further. S. sanguis 2017-78 caused the phosphorylation of p38 MAP kinase and subsequently cPLA2. The p38 MAP kinase inhibitor, SB203580 inhibited S. sanguis 2017-78-induced platelet aggregation as well as the phosphorylation of both p38 MAP kinase and cPLA2. These data are consistent with cPLA2 as a physiological target of p38.
A second component of the study examined the effects of aspirin, a known inhibitor of cyclooxygenase, on these signalling pathways.
|
20 |
Untersuchungen über die Zahl der Blutplättchen Inaugural-Dissertation /Dreyer, Kurt, January 1900 (has links)
Thesis (doctoral)--Bayerische Ludwig Maximilians Universität, Munich, 1933.
|
Page generated in 0.0294 seconds